CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On May23, 2018, Cara Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its entry into a license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd, and the Company’s related conference call to be held at 8:30 a.m. EDT on May23, 2018. Copies of the press release and the presentation to be discussed on the conference call are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference. The information furnished under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

(d) Exhibits.

Cara Therapeutics, Inc. Exhibit
EX-99.1 2 d593778dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus Cara receives upfront payment of $50 million in cash and an equity investment of $20 million Cara eligible for up to $470 million in regulatory and commercial milestones VFMCRP to commercialize KORSUVA injection worldwide except in the U.S.,…
To view the full exhibit click here

About CARA THERAPEUTICS, INC. (NASDAQ:CARA)

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.